NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $0.96 -0.09 (-8.48%) As of 02:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About INmune Bio Stock (NASDAQ:INMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get INmune Bio alerts:Sign Up Key Stats Today's Range$0.89▼$1.0650-Day Range$1.05▼$2.5152-Week Range$0.89▼$2.60Volume341,579 shsAverage Volume479,703 shsMarket Capitalization$29.75 millionP/E RatioN/ADividend YieldN/APrice Target$2.50Consensus RatingModerate Buy Company Overview INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company’s research focuses on using immune responses to address cancer and inflammatory conditions, including neuroinflammation. Its pipeline includes XPro1595, a selective inhibitor of soluble tumor necrosis factor being studied for conditions including Alzheimer’s disease, and INKmune, an investigational cell therapy designed to enhance natural killer cell activity against cancer. These therapies remain under clinical development. INmune Bio is headquartered in La Jolla, California. The company is led by Raymond J. Tesi, M.D., its co-founder, president and chief executive officer.AI Generated. May Contain Errors. Read More INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreINMB MarketRank™: 2.111228953995 of 5 starsINmune Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 694th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingINmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialINmune Bio has a consensus price target of $2.50, representing about 175.6% upside from its current price of $0.91.Amount of Analyst CoverageINmune Bio has only been the subject of 2 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.93% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently decreased by 7.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.81 News SentimentINmune Bio has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for INmune Bio this week, compared to 2 articles on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INMB Stock News HeadlinesINmune Bio Inc. (INMB) Q3 2026 Earnings Call Prepared Remarks TranscriptNovember 8, 2026 | seekingalpha.comINmune Bio (NASDAQ:INMB) Rating Lowered to "Sell" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comWhy my scanner is $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 16 at 1:00 AM | Profits Run (Ad)INmune Bio (INMB) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | fool.comINmune Bio Inc (INMB) Q3 2026 Earnings Call Highlights: UK Approval Path for Ebstracell Narrows ...November 6, 2026 | finance.yahoo.comINmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business UpdateNovember 5, 2026 | globenewswire.comINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thOctober 29, 2026 | globenewswire.comINmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private PlacementOctober 28, 2026 | globenewswire.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $1.56 at the beginning of 2026. Since then, INMB stock has decreased by 41.9% and is now trading at $0.9070. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. Read the conference call transcript. When did INmune Bio IPO? INmune Bio (INMB) raised $20 million in an initial public offering (IPO) on the week of February 4th 2019. The company issued 2,500,000 shares at a price of $8.00 per share. Who are INmune Bio's major shareholders? Top institutional investors of INmune Bio include State Street Corp (0.42%), Marshall Wace LLP (0.29%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss and Scott Juda. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include Cassava Sciences (FLNA), NVIDIA (NVDA), Palantir Technologies (PLTR), Plug Power (PLUG), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings11/05/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, INMB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Price Target for INmune Bio$2.50 High Price Target$2.50 Low Price Target$2.50 Potential Upside/Downside+170.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.71% Return on Assets-62.58% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book1.05Miscellaneous Outstanding Shares30,959,000Free Float24,334,000Market Cap$28.67 million OptionableOptionable Beta0.97 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:INMB) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.